Diarylthiohydantoin compound as androgen receptor antagonist

US11332465B2 · kind B2 · utility

Assignee

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

• Chunli Shen · Shanghai, CN
• Chengde Wu · Shanghai, CN
• Shenglin Chen · Shanghai, CN
• Shuhui CHEN · Shanghai, CN
• Xiquan Zhang · 安丰镇, CN
• Xin Tian · 安丰镇, CN

Key dates

• Filing date: Aug 7, 2018
• Grant date: May 17, 2022
• Expiry date: Aug 7, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.